| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0889-8529(02)00077-4 |
| P698 | PubMed publication ID | 12699294 |
| P2093 | author name string | Markus J Seibel | |
| P2860 | cites work | Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: Effects of estrogen therapy | Q71877357 |
| Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis | Q72269383 | ||
| Urinary excretion of pyridinium crosslinks of collagen in oophorectomized women as markers for bone resorption | Q72406693 | ||
| Effect of salmon calcitonin on deoxypyridinoline (Dpyr) urinary excretion in healthy volunteers | Q72571077 | ||
| Differences in serum bone GLA protein with age and sex | Q72571686 | ||
| Impairment of bone turnover in elderly women with hip fracture | Q72612906 | ||
| To determine the effects of ultraviolet light, natural light and ionizing radiation on pyridinium cross-links in bone and urine using high-performance liquid chromatography | Q73024229 | ||
| Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis | Q73132752 | ||
| High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women | Q73153001 | ||
| Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome | Q73754830 | ||
| Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis | Q73906732 | ||
| Abnormal bone turnover in long-standing Crohn's disease in remission | Q73941989 | ||
| Rapid bone loss is associated with increased levels of biochemical markers | Q74293153 | ||
| Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group | Q74594698 | ||
| The Tromsø Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women | Q77205944 | ||
| Bone metabolism during the perimenopausal transition: a prospective study | Q77541717 | ||
| A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover | Q77900655 | ||
| Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study | Q31811836 | ||
| Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture | Q33567611 | ||
| Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women | Q33896976 | ||
| Intravenous zoledronic acid in postmenopausal women with low bone mineral density | Q34116443 | ||
| Effect of alendronate on bone mineral density in male idiopathic osteoporosis | Q34320174 | ||
| Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study | Q34404537 | ||
| Relationship of bone turnover to bone density and fractures | Q34430413 | ||
| Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment | Q35591340 | ||
| Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study | Q36596562 | ||
| Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH‐deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass | Q36684692 | ||
| Serum osteocalcin and fracture susceptibility in elderly women | Q36772922 | ||
| Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women | Q36794744 | ||
| Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis | Q40664389 | ||
| Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment | Q40704945 | ||
| Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy | Q41087577 | ||
| Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause? | Q41101356 | ||
| Screening procedure for women at risk of developing postmenopausal osteoporosis | Q41181598 | ||
| Increased bone formation in osteocalcin-deficient mice. | Q41182577 | ||
| Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption | Q41673161 | ||
| The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial | Q41687967 | ||
| Increased bone resorption in moderate smokers with low body weight: the Minos study | Q42166285 | ||
| Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment | Q42631192 | ||
| The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 | ||
| Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy | Q43601705 | ||
| Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women | Q43601777 | ||
| Cross-linking and new bone collagen synthesis in immobilized and recovering primate osteoporosis | Q67251454 | ||
| Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing | Q67504223 | ||
| Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level | Q67593029 | ||
| Biochemical parameters associated with low bone density in healthy men and women | Q67596868 | ||
| Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck | Q67867755 | ||
| Prediction of bone loss in postmenopausal women | Q67981651 | ||
| The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years | Q68003378 | ||
| Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover | Q68354011 | ||
| Determinants of bone gamma-carboxyglutamic acid-containing protein in plasma of healthy aging subjects | Q69867983 | ||
| Osteocalcin in normal adult humans of different sex and age | Q69868221 | ||
| Prediction of rapid bone loss in postmenopausal women | Q69898503 | ||
| Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism | Q70170959 | ||
| Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption | Q70483489 | ||
| The stability of pyridinium crosslinks in urine and serum | Q70952585 | ||
| Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures | Q70981498 | ||
| Bone density change and biochemical indices of skeletal turnover | Q71141484 | ||
| Effects of continuous glucocorticoid infusion on bone metabolism in the rat | Q71226763 | ||
| Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study | Q71345169 | ||
| Bone alkaline phosphatase measured with a new immunoradiometric assay in patients with metabolic bone diseases | Q71510461 | ||
| Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy | Q71571037 | ||
| Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis | Q71644718 | ||
| A comparison of the effects of parathyroid hormone and parathyroid hormone-related protein on osteocalcin in the rat | Q71773685 | ||
| Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women | Q71802428 | ||
| Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity | Q43601789 | ||
| Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate | Q43649424 | ||
| Response of biochemical markers of bone turnover to estrogen treatment in post-menopausal women: evidence against an early anabolic effect on bone formation | Q43659724 | ||
| The effect of fluvastatin on parameters of bone remodeling | Q43667175 | ||
| Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women | Q43703736 | ||
| Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women | Q43722752 | ||
| Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia | Q43732502 | ||
| Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis | Q43755577 | ||
| The relation between lifestyle factors and biochemical markers of bone turnover among early postmenopausal women | Q43782121 | ||
| Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. | Q43791669 | ||
| Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women | Q43814224 | ||
| Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis | Q43855578 | ||
| Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women | Q43866544 | ||
| Changes in biochemical markers of bone turnover in women treated with raloxifene: influence of regression to the mean | Q43887173 | ||
| Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis | Q43913796 | ||
| Vitamin K counteracts the effect of warfarin in liver but not in bone | Q44340856 | ||
| Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links | Q45195858 | ||
| Direct demonstration that the vitamin K-dependent bone Gla protein is incompletely gamma-carboxylated in humans | Q46171036 | ||
| Secondary hyperparathyroidism and bone turnover in elderly blacks and whites | Q46507421 | ||
| Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. | Q47857557 | ||
| Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. | Q50599684 | ||
| Biochemical markers of bone turnover reflect femoral bone loss in elderly women. | Q50616499 | ||
| Can biochemical markers predict bone loss at the hip and spine?: a 4-year prospective study of 141 early postmenopausal women. | Q50617881 | ||
| Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. | Q50687392 | ||
| Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study. | Q50754152 | ||
| Diurnal variation of bone mineral turnover in elderly men and women. | Q50960402 | ||
| Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. | Q50966362 | ||
| Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. | Q51564493 | ||
| Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics. | Q51580719 | ||
| Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen | Q51593199 | ||
| Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women. | Q51595501 | ||
| Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis. | Q51597937 | ||
| The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. | Q51618100 | ||
| Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. | Q52370916 | ||
| Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. | Q52707875 | ||
| Circadian variation of different fractions of serum acid phosphatase | Q52712335 | ||
| Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. | Q53778382 | ||
| Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. | Q53884705 | ||
| Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) | Q53964919 | ||
| Acute effects of bisphosphonates on new and traditional markers of bone resorption | Q54168669 | ||
| Increased bone resorption and decreased bone formation in Chinese patients with hip fracture. | Q54174310 | ||
| Hormone Replacement Therapy in Postmenopausal Women: Urinary N-Telopeptide of Type I Collagen Monitors Therapeutic Effect and Predicts Response of Bone Mineral Density | Q57224710 | ||
| Influence of Ovariectomy and Estradiol Treatment on Calcium Homeostasis During Aging in Rats | Q60777495 | ||
| Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption | Q60777504 | ||
| Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a pilot study | Q60777505 | ||
| Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis | Q60777509 | ||
| Estrogen Protection against Bone Resorbing Effects of Parathyroid Hormone Infusion: Assessment by Use of Biochemical Markers | Q60777510 | ||
| Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion | Q61238160 | ||
| Episodic Changes of Serum ProcoUagen Type I Carboxy-Terminal Propeptide Levels in Fertile and Postmenopausal Women | Q61855128 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 83-113, vi-vii | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Endocrinology and Metabolism Clinics of North America | Q15763298 |
| P1476 | title | Biochemical markers of bone remodeling. | |
| P478 | volume | 32 |
| Q37098360 | Adverse bone health among children and adolescents growing up with HIV. |
| Q36656424 | Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls |
| Q38034435 | Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group |
| Q34429852 | Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study |
| Q34265281 | Cathepsin K in treatment monitoring following intravenous zoledronic acid |
| Q79080510 | Celiac Disease: A Bone Perspective |
| Q34069692 | Chronic kidney disease and bone fracture: a growing concern |
| Q89532420 | Circulating Undercarboxylated Osteocalcin as Estimator of Cardiovascular and Type 2 Diabetes Risk in Metabolic Syndrome Patients |
| Q36277211 | Clinical use of markers of bone turnover in metastatic bone disease. |
| Q44104794 | Conformity in diversity? Isotopic investigations of infant feeding practices in two iron age populations from Southern Öland, Sweden |
| Q112876346 | Diet in transitory society: isotopic analysis of medieval population of Central Europe (ninth–eleventh century AD, Czech Republic) |
| Q116942015 | Dietary reconstruction of the Moravian Lombard population (Kyjov, 5th–6th centuries AD, Czech Republic) through stable isotope analysis (δ13C, δ15N) |
| Q50542966 | Effects of resistance training on biomarkers of bone formation and association with red blood cell variables. |
| Q34701705 | Effects of thiazolidinediones on bone loss and fracture |
| Q36338679 | Endocrine regulation of bone turnover in men. |
| Q39161796 | Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females |
| Q28817706 | Inflammation as a contributing factor among postmenopausal Saudi women with osteoporosis |
| Q39343264 | Influence of multilayer rhBMP-2 DNA coating on the proliferation and differentiation of MC3T3-E1 cells seeded on roughed titanium surface |
| Q46655041 | Low bone turnover phenotype in Rett syndrome: results of biochemical bone marker analysis |
| Q89619541 | Ovariectomized rat model of osteoporosis: a practical guide |
| Q37208450 | Pediatric vitamin D and calcium nutrition in developing countries |
| Q34196596 | The effect of metyrosine/prednisolone combination to oophorectomy-induced osteoporosis. |
| Q33278926 | The effect of oxandrolone treatment on human osteoblastic cells. |
| Q37027538 | The role of hyperhomocysteinemia as well as folate, vitamin B(6) and B(12) deficiencies in osteoporosis: a systematic review |
| Q28263140 | The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects |
| Q36990793 | The use of molecular markers of bone turnover in the management of patients with metastatic bone disease |
| Q35277934 | Urban and rural infant-feeding practices and health in early medieval Central Europe (9th-10th Century, Czech Republic). |
| Q37290052 | Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis |
| Q80994121 | [Bone mineral loss in patients with human immunodeficiency virus infection] |
Search more.